Inhibikase Therapeutics (IKT) Stock Chart & Stock Price History $1.55 -0.17 (-9.88%) As of 09/25/2025 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock Inhibikase Therapeutics Stock Price Performance The Inhibikase Therapeutics (IKT) stock chart highlights key performance trends across multiple timeframes. As of the latest close, Inhibikase Therapeutics traded at $1.55 with a market cap of $115.51 million and volume of 79,503 shares. Receive IKT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. 5 Day Performance-5.49% IKT Stock Chart for Friday, September, 26, 2025 IKT Chart by TradingView Inhibikase Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization09/25/2025$1.72$1.55-9.88%$1.72$1.5379,503 shs$115.51 million09/24/2025$1.62$1.72+6.17%$1.75$1.61230,668 shs$128.17 million09/23/2025$1.68$1.62-3.57%$1.72$1.6096,401 shs$120.72 million09/22/2025$1.64$1.68+2.44%$1.70$1.56104,248 shs$125.19 million09/19/2025$1.54$1.64+6.49%$1.78$1.47825,748 shs$122.21 million09/18/2025$1.56$1.54-1.28%$1.61$1.52249,759 shs$114.76 million09/17/2025$1.56$1.56$1.63$1.56107,207 shs$116.25 million09/16/2025$1.60$1.56-2.50%$1.60$1.5557,447 shs$116.25 million09/15/2025$1.56$1.60+2.56%$1.60$1.50157,294 shs$119.23 million09/12/2025$1.68$1.56-7.14%$1.68$1.5578,545 shs$116.25 million Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 09/11/2025$1.54$1.68+9.09%$1.73$1.5097,991 shs$125.19 million09/10/2025$1.67$1.54-7.78%$1.64$1.53107,764 shs$114.76 million09/09/2025$1.66$1.67+0.60%$1.68$1.6033,250 shs$124.45 million09/08/2025$1.67$1.66-0.60%$1.73$1.6548,546 shs$123.70 million09/05/2025$1.71$1.67-2.34%$1.70$1.66209,450 shs$124.44 million09/04/2025$1.73$1.71-1.16%$1.73$1.6675,322 shs$127.43 million09/03/2025$1.76$1.73-1.70%$1.80$1.71113,579 shs$128.92 million09/02/2025$1.80$1.76-2.22%$1.84$1.7688,230 shs$131.15 million09/01/2025N/A$1.80$1.85$1.7871,026 shs$0.00 Related Companies Bicycle Therapeutics Stock Chart COMPASS Pathways Stock Chart Compass Therapeutics Stock Chart REGENXBIO Stock Chart iTeos Therapeutics Stock Chart Corvus Pharmaceuticals Stock Chart Zhengye Biotechnology Stock Chart Prothena Stock Chart Alumis Stock Chart Zevra Therapeutics Stock Chart Receive IKT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:IKT) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
